Morningstar

Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

JUPITER, Fla., June 9, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the U ...
Morningstar

Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma

JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB ...
GEN

Myosin-Targeting Drug Sensitizes Glioblastoma to Treatment in Mice

Each year, about 14,000 people in the United States are diagnosed with glioblastoma, one of the deadliest primary brain tumors. With standard treatments of surgery, radiation, and chemotherapy ...
Cure Today

FDA Fast Tracks MT-125 for Glioblastoma

MT-125, a selective inhibitor of non-muscle myosin II, targets glioblastoma's tumor proliferation and resistance mechanisms. The FDA's fast track designation aims to expedite MT-125's development and ...